In the past week, BCAB stock has gone up by 41.01%, with a monthly gain of 15.29% and a quarterly plunge of -30.74%. The volatility ratio for the week is 15.82%, and the volatility levels for the last 30 days are 11.78% for BioAtla Inc The simple moving average for the last 20 days is 20.54% for BCAB stock, with a simple moving average of -9.07% for the last 200 days.
Is It Worth Investing in BioAtla Inc (NASDAQ: BCAB) Right Now?
The stock has a 36-month beta value of 1.04. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCAB is 38.96M, and at present, short sellers hold a 10.26% of that float. On August 19, 2024, the average trading volume of BCAB was 950.04K shares.
BCAB) stock’s latest price update
BioAtla Inc (NASDAQ: BCAB)’s stock price has plunge by 3.16relation to previous closing price of 1.90. Nevertheless, the company has seen a 41.01% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-11 that BioAtla, Inc. (NASDAQ:BCAB ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Bruce Mackle – LifeSci Advisors, IR Dr. Jay Short – Chairman, Co-Founder and CEO Richard Waldron – Chief Financial Officer Dr. Eric Sievers – Chief Medical Officer Sheri Lydick – Chief Commercial Officer Conference Call Participants Brian Cheng – JPMorgan Arthur He – H.C. Wainwright Operator Good day, everyone.
Analysts’ Opinion of BCAB
Many brokerage firms have already submitted their reports for BCAB stocks, with JMP Securities repeating the rating for BCAB by listing it as a “Mkt Outperform.” The predicted price for BCAB in the upcoming period, according to JMP Securities is $17 based on the research report published on September 15, 2022 of the previous year 2022.
Credit Suisse, on the other hand, stated in their research note that they expect to see BCAB reach a price target of $5, previously predicting the price at $35. The rating they have provided for BCAB stocks is “Neutral” according to the report published on May 05th, 2022.
H.C. Wainwright gave a rating of “Buy” to BCAB, setting the target price at $25 in the report published on March 21st of the previous year.
BCAB Trading at 24.47% from the 50-Day Moving Average
After a stumble in the market that brought BCAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.24% of loss for the given period.
Volatility was left at 11.78%, however, over the last 30 days, the volatility rate increased by 15.82%, as shares surge +14.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.61% upper at present.
During the last 5 trading sessions, BCAB rose by +43.17%, which changed the moving average for the period of 200-days by +35.38% in comparison to the 20-day moving average, which settled at $1.6385. In addition, BioAtla Inc saw -20.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCAB starting from MCBRINN SYLVIA, who purchase 4,000 shares at the price of $2.33 back on Dec 26 ’23. After this action, MCBRINN SYLVIA now owns 15,125 shares of BioAtla Inc, valued at $9,320 using the latest closing price.
SHORT JAY M PHD, the Chief Executive Officer of BioAtla Inc, purchase 50,000 shares at $2.14 during a trade that took place back on Dec 20 ’23, which means that SHORT JAY M PHD is holding 1,439,283 shares at $106,910 based on the most recent closing price.
Stock Fundamentals for BCAB
Current profitability levels for the company are sitting at:
- -64.47 for the present operating margin
- 0.35 for the gross margin
The net margin for BioAtla Inc stands at -61.29. The total capital return value is set at -2.15. Equity return is now at value -134.14, with -84.23 for asset returns.
Based on BioAtla Inc (BCAB), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -64.55. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -74.82.
Currently, EBITDA for the company is -128.47 million with net debt to EBITDA at 0.55. When we switch over and look at the enterprise to sales, we see a ratio of 20.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.81.
Conclusion
To sum up, BioAtla Inc (BCAB) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
